Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy
Iron overload was a common complication in patients with chronic renal failure treated with dialysis prior to the availability of recombinant human erythropoietin (rHuEPO) therapy. Iron overload was the result of hypoproliferative erythroid marrow function coupled with the need for frequent red blood cell transfusions to manage symptomatic anemia. The repetitive use of intravenous iron with or without the use of red blood cell transfusions also contributed to iron loading and was associated with iron deposition in liver parenchymal and reticuloendothelial cells; however, there were no abnormal liver function tests or evidence of cirrhosis unless viral hepatitis resulted from the transfusions. With rHuEPO therapy, the excess iron stores were shifted back into circulating red blood cells as the anemia was partially corrected, and red blood cells were lost from circulation by the hemodialysis procedure. After several years of rHuEPO therapy, most hemodialysis patients required iron supplements to replace the continuing blood losses related to hemodialysis. The potential complications of iron overload (parenchymal iron deposition, permanent organ damage, increased risk of bacterial infections, and increased free radical generation)...Continue Reading
High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men
Correction of deficient phagocytosis during erythropoietin treatment in maintenance hemodialysis patients
The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy
Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy
Recombinant erythropoietin reverses polymorphonuclear granulocyte dysfunction in iron-overloaded dialysis patients
Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin
Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients
Critical role of iron overload in the increased susceptibility of haemodialysis patients to bacterial infections. Beneficial effects of desferrioxamine
Twenty-four hour variation of transferrin saturation in treated and untreated haemochromatosis homozygotes
Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
Serum ferritin in haemodialysis patients: is there a relationship to 'haemochromatosis alleles' HLA A3, B7, B14?
Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial
iron-overload-associated myopathy in patients on maintenance haemodialysis: a histocompatibility-linked disorder
Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy
Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment
Neutrophil impairment associated with iron therapy in hemodialysis patients with functional iron deficiency.
EPIBACDIAL: a multicenter prospective study of risk factors for bacteremia in chronic hemodialysis patients.
Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project
Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients
Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study
Increased Dietary Salt Changes Baroreceptor Sensitivity and Intrarenal Renin-Angiotensin System in Goldblatt Hypertension
Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats
Differential response of iron metabolism to oxidative stress generated by antimycin A and nitrofurantoin
Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease
The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?
Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease
Iron-containing pathologies of the spleen: magnetic resonance imaging features with pathologic correlation.
Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis
Histological Scores Validate the Accuracy of Hepatic Iron Load Measured by Signal Intensity Ratio and R2* Relaxometry MRI in Dialysis Patients
Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.